Publications by authors named "Beatriz Montull"
Background: The published experience of lung transplantation in acute respiratory distress syndrome (ARDS) is limited. The aim of this study was to investigate the contemporary results of lung transplantation attempts in ARDS in major European centres.
Methods: We conducted a retrospective multicentre cohort study of all patients listed for lung transplantation between 2011 and 2019.
Background: Scedosporium species and Lomentospora prolificans (Sc/Lp) are emerging molds that cause invasive disease associated with a high mortality rate. After Aspergillus, these molds are the second filamentous fungi recovered in lung transplant (LT) recipients.
Aims: Our objective was to evaluate the incidence, risk factors and outcome of Sc/Lp infections in LT recipients at a tertiary care hospital with a national reference LT program.
Bronchiectasis is a chronic structural disease associated with exacerbations that provoke systemic inflammation. We aimed to evaluate the systemic acute proinflammatory cytokine and its biomarker profiles during and after exacerbations and its relationship with the severity of episode, microbiological findings, and the bronchiectasis severity index. This prospective observational study compared exacerbation and stable groups.
View Article and Find Full Text PDFObjectives: Despite the clinical relevance of exacerbations in bronchiectasis (BE), little is known about the microbiology and outcomes of pneumonic (CAP) vs. non-pneumonic (NOCAP) exacerbations.
Methods: This study compares clinical and microbiological characteristics of CAP vs.
Community-acquired pneumonia (CAP) is a serious infection that may occasionally rapidly evolve provoking organ dysfunctions. We aimed to characterize CAP presenting with organ dysfunctions at the emergency room, with regard to host factors and causative microorganisms, and its impact on 30-day mortality. 460 of 4070 (11.
View Article and Find Full Text PDFBackground: Severe sepsis, may be present on hospital arrival in approximately one-third of patients with community-acquired pneumonia (CAP).
Objective: To determine the host characteristics and micro-organisms associated with severe sepsis in patients hospitalized with CAP.
Results: We performed a prospective multicenter cohort study in 13 Spanish hospital, on 4070 hospitalized CAP patients, 1529 of whom (37.
Background: Limited information is available about clinical outcomes and microbiology of community-acquired pneumonia in asthma.
Methods: We prospectively studied 4079 CAP patients over a 12-years period and found 139 (3.4%) asthmatic patients.
Introduction: Treatment failure in community-acquired-pneumonia (CAP) patients is associated with a high mortality rate, and therefore are a matter of great concern in clinical management. Those patients have increased mortality and are a target population for randomized clinical trials.
Methods: A case-control study was performed in patients with CAP (non-failure cases vs.
Background And Objective: The previous use of inhaled corticosteroids (ICS) may reduce the inflammatory response and mortality in patients with community-acquired pneumonia (CAP).
Methods: We measured serum levels of several inflammatory biomarkers, as well as mortality at various time-points, in 663 consecutive patients hospitalized for CAP; 128 (19%) were receiving chronic outpatient treatment with ICS. Patients on previous oral corticosteroids were excluded from the analysis.
Background: Community-acquired pneumonia (CAP) is a frequent event in patients with COPD, although it is not currently considered an acute exacerbation of COPD (AECOPD). To our knowledge, no studies have compared the inflammatory response of patients with COPD who develop CAP or AECOPD. The aim of our study was to compare clinical and evolutive manifestations and biologic signaling of AECOPD and CAP + COPD.
View Article and Find Full Text PDFBackground: Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has been recently associated with increased mortality in hospitalized patients with community-acquired pneumonia (CAP). We assessed the characteristics and outcomes of patients with CAP and thrombocytosis (platelet count ≥ 4 × 105/mm3) compared with thrombocytopenia (platelet count < 105/mm3) and normal platelet count.
Methods: We prospectively analyzed 2,423 consecutive, hospitalized patients with CAP.
Background: Several clinical studies have evaluated the role of COPD in patients with community acquired pneumonia (CAP). We investigated the systemic inflammatory response of patients with CAP (CAP 1 COPD) and patients without associated COPD (CAP only).
Methods: Clinical, microbiologic, and immunologic data were collected from 367 prospective patients on admission to hospital during a 3-year period.
Background And Objective: Although the benefits of systemic corticosteroids in community-acquired pneumonia (CAP) are not clear, their use is frequent in clinical practice. We described the frequency of this practice, patients' characteristics and its clinical impact.
Methods: We investigated all adult CAP patients visited between June 1997 and January 2008 (n = 3257).
Biomarkers and community-acquired pneumonia: tailoring management with biological data.
Semin Respir Crit Care Med
June 2012
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases worldwide, with an incidence of 0.3 to 0.5% in the adult population.
View Article and Find Full Text PDFBackground: The inflammatory response in community-acquired pneumonia (CAP) depends on the host and on the challenge of the causal microorganism. Here, we analyze the patterns of inflammatory cytokines, procalcitonin (PCT), and C-reactive protein (CRP) in order to determine their diagnostic value.
Methods: This was a prospective study of 658 patients admitted with CAP.